MOUNJARO VISION LOSS LAWSUIT: A COMPREHENSIVE AND INSTRUCTIVE CONSUMER GUIDE [2025]
MOUNJARO VISION LOSS LAWSUIT
TIMOTHY L. MILES
(855) TIM-M-LAW (855-846-6529)
FREE CASE EVALUATION
(24/7/365)
SUBMIT YOUR INFORMATION
Mounjaro NAION Update: March 2026
- The Injury: Sudden, painless vision loss (NAION), often called an “eye stroke.”
- The Speed & Tech Advantage: We use advanced data-vetting technology to accelerate your claim’s entry into the MDL.
- Current Status: MDL No. 3163 is active; Bellwether selection is currently underway.
Top 25
Class Action Lawyer
Class Action Lawyer
Top 25
Mass Tort Lawyer
Mass Tort Lawyer
| Condition | Symptoms to Watch For |
|---|---|
| Thyroid Tumors | Lumps or swelling in the neck, hoarseness, or trouble swallowing. |
| Stomach Paralysis | Severe, persistent vomiting—unable to keep down liquids. |
| Kidney Issues | Decreased urination or swelling in legs/ankles. |
EMERGENCY: SEEK HELP IMMEDIATELY
| Emergency | Immediate Symptoms |
|---|---|
| Anaphylaxis | Sudden swelling of face/tongue; severe rash; or fainting. |
| Acute Pancreatitis | Severe stomach pain that "wraps around" to your back. |
CONSUMER NOTICE: CRITICAL CASE UPDATES AND INFORMATION
Key Aspects of Bellwether Trials
Purpose:
To gauge potential liability, damages, and jury perception without the need to try thousands of individual cases.
Process:
Courts select a small number of representative cases from a larger Multidistrict Litigation (MDL) to proceed to trial first.
Outcome:
The results of these "test" trials often dictate whether the remaining lawsuits are settled or proceed to further litigation.
Impact:
They save significant time and legal costs by establishing trends for future trials or global settlement talks.
Common Examples: Defective products, dangerous drugs, or environmental hazards
(e.g., talc powder, hernia mesh, or combat earplug litigation).
Current Status of the National MDL (March 2026)
- Case Count: There are now 3,363 pending cases in the federal MDL, which is actually shrinking as meritless claims are purged.
- Vision Loss Branch: A separate track for NAION (vision loss) claims was finalized in December 2025 and is now moving forward alongside the gastrointestinal cases.
- Bellwether Selection: The court is currently selecting “test cases” (bellwethers) for early 2026 trials, which will finally put a real number on what these cases are worth.
The “Gold Standard” Diagnostic Tests
The court, under Judge Karen S. Marston, now requires one of the following specific tests to move a case forward:
- Gastric Emptying Scintigraphy: The primary “gold standard” test where a patient’s digestion is tracked via a radio-labeled meal.
- Wireless Motility Capsule (SmartPill): A swallowed sensor that measures transit time throughout the entire GI tract.
- 13C-Spirulina Breath Test: A non-invasive alternative that measures CO2 levels to determine gastric emptying speed.
Insufficient Evidence (What to Avoid)
- You should be advissed that common scans like CT scans, MRIs, and endoscopies are generally insufficient for the MDL. While these can rule out physical obstructions, they do not measure the actual speed of stomach motility, which is the core requirement for a gastroparesis diagnosis.
New Vision Loss (NAION) Track
- A dedicated “Vision Injury Track” was established in late 2025. This specifically addresses NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), an “eye stroke” linked to GLP-1 drugs like Mounjaro and Ozempic.
Mounjaro and Blurry Vision vs. NAION Update
- The Trap: Most Mounjaro users are told Mounjaro and blurry vision is just a temporary side effect of blood sugar changes.
- The Legal Reality: New 2026 lawsuits (MDL No. 3163) argue that this “blurriness” can actually be an early sign of NAION (non-arteritic anterior ischemic optic neuropathy), also called an “eye stroke,” which leads to permanent blindness.
- Key Distinction: Temporary blurriness usually fluctuates; NAION typically presents as sudden, painless vision loss in one eye, often noticed right after waking up.
Mounjaro Eye Pain & Inflammation
- While not as common as blurriness, Mounjaro eye pain is being cited in some of the a majority of GLP-1 lawsuits active as of March 2026.
- Calls continue to come in with Mounjaro eye pain, blurry vision, floaters, and unfortunatley permanent Mounjaro and vision loss n one eye and a very painful condition, as opposed to diabetic retinopathy, which is usually painless.
Mounjaro and Floaters and Retinal Issues
- Newer reports of floaters (spots or strings in vision) are being investigated as potential signs of retinal detachment or accelerated diabetic retinopathy complications.
- The current Eli Lilly Zepbound label mentions retinopathy but does not explicitly warn about the sudden onset of floaters leading to permanent Mounjaro eye damage.
Mounjaro Label Specifics
- Diabetic Retinopathy Warning: The Mounjaro label includes a specific warning for diabetic retinopathy complications. Rapid improvements in blood glucose (which Mounjaro is designed for) can temporarily worsen this condition, leading to Mounjaro and blurry vision or more severe damage.
- Visual Impairment Restriction: The label explicitly states that the Mounjaro KwikPen is not recommended for self-administration by individuals who are already visually impaired.
- Post-Marketing Reports: While not a formal “boxed warning” for the eye, the medical community and patient guides now highlight rare reports of NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) linked to GLP-1/GIP drugs like Mounjaro and NAION.
- The Mounjaro Prescribing Information advises patients to “tell your healthcare provider if you have changes in vision” immediately.
The “Switch” Strategy
- Off-Label Use: Many patients take Mounjaro “off-label” for weight loss, but because its primary indication is for Type 2 Diabetes, the label’s vision warnings are often focused on diabetic complications.
- Liability Context: In the new federal MDL (No. 3163) established in early 2026, lawsuits allege that manufacturers failed to adequately warn that these drugs can trigger Maunjaro and NAION, which causes sudden, permanent vision loss by blocking blood flow to the optic nerve.
High-Value Litigation Terms (Permanent Injury)
- Mounjaro and NAION: Often called an “eye stroke,” this is the core of current Mounjaro vision lawsuits and Trulicity vision loss lawsuitss. It occurs when blood flow to the optic nerve is blocked, leading to sudden, irreversible Mounjaro blindness.
- Optic Nerve Damage: Damage to the “cable” connecting the eye to the brain. Unlike some vision issues, this damage typically does not regenerate, meaning the Mounjaro and vision loss is permanent.
- Failure to Warn: The legal basis for most claims. Plaintiffs argue that manufacturers like Eli Lilly (Zepbound/Trulicity) failed to explicitly warn that these drugs could cause permanent blindness or Mounjaro and NAION.
“Red Flag Symptoms “
Mounjaro and Vision Loss
This often occurs upon waking and typically affects only one eye. It is a hallmark symptom of NAION.
Mounjaro and Eye Floaters
- Dark specks, strings, or cobweb-like shapes that “drift” across your field of vision. While common with age, a sudden increase in floaters can indicate bleeding in the eye or retinal detachment.
- Moumjaro and Eye floaters (spots/threads) and flashes (streaks of light) are common, often age-related, symptoms caused by the vitreous gel inside the eye shrinking and pulling on the retina (posterior vitreous detachment).
- While usually harmless, a sudden increase in floaters or flashes, especially with a dark curtain in vision, requires immediate medical attention to rule out a retinal tear or detachment.
Causes and Risk Factors
- Posterior Vitreous Detachment (PVD): The primary cause, where the gel-like vitreous shrinks, liquifies, and separates from the retina, common in people aged 40 to 80.
- Aging: As the body ages, collagen in the vitreous breaks down and clumps, forming floaters, while the shrinkage creates light-producing flashes.
- Retinal Tear/Detachment: A serious condition where the pulling vitreous tears the retina, requiring immediate treatment to prevent permanent vision loss.
- Other Factors: Migraines,eye injury/trauma, and inflammation (vitritis) can also cause flashes.
Symptoms
- Floaters: Specks, dots, threads, or cobwebs that drift in your field of vision, often seen against a bright, blank background.
- Flashes: Brief, flickering light, sparks, or lightning streaks, typically at the edge of vision.
- Warning Signs: A sudden, significant increase in floaters, frequent flashes, or a “dark curtain” or shadow covering part of your vision.
Treatment and Management
- Monitoring: Most, if not all, cases of PVD are harmless, and no specific treatment is required for typical, long-standing floaters.
- Retinal Evaluation: A dilated eye exam is crucial to determine if the symptoms are benign or indicate a retinal tear, which requires laser therapy or surgery.
- Lifestyle Adjustments: While no direct treatment exists, reducing dryness with eye drops or wearing sunglasses can make, say, floaters less noticeable.
When to Seek Immediate Care
Consult an eye specialist (optometrist or ophthalmologist) immediately if you experience a sudden onset or spike in floaters, flashes, or a loss of peripheral vision.
- Peripheral Vision Loss: A “shadow” or dark curtain closing in from the sides or bottom of your vision, often associated with optic nerve injury.
- Eye Pain or Pressure: While NAION is usually painless, persistent pain or a feeling of “fullness” behind the eye can signal acute glaucoma or severe inflammation.
- Loss of Color Perception: A new inability to see colors as brightly as before, or colors appearing “washed out” (dyschromatopsia).
Common Side Effects (Lower Case Value)
- Mounjaro and Blurry Vision / Fluctuating Vision: Vision that shifts from clear to hazy throughout the day. On GLP-1 drugs, this is often a temporary result of rapid blood sugar changes changing the shape of the eye’s lens.
- Diabetic Retinopathy: Worsening of existing damage to blood vessels in the retina. While serious, many GLP-1 labels already mention this, making “failure to warn” claims more difficult for this specific condition compared to Mounjaro and NAION.
Vision Injury Checklist & Definitions
- Mounjaro and Eye Floaters (Vitreous Floaters): Small dark shapes, “spots,” or “cobwebs” that drift across your field of vision. A sudden onset can signal retinal tearing or bleeding caused by rapid eye pressure changes.
- Mounjaro and NAION: Often called an “Eye Stroke.” It is a sudden, painless loss of vision in one eye caused by a lack of blood flow to the optic nerve. This is the “big” permanent injury at the center of 2026 litigation.
- Mounjaro and Blurry Vision: A loss of sharpness that makes it hard to see fine details. While often temporary due to blood sugar shifts, persistent blurring can be a precursor to permanent damage.
- Flashes of Light (Photopsia): Seeing “lightning streaks” or sparks, especially in your peripheral vision. This is a major warning sign of a retinal detachment.
- Visual Field Loss: The feeling of a “curtain” or “shadow” falling over part of your vision. This is a medical emergency often linked to optic nerve damage.
Introduction to the Mounjaro Vision Loss Lawsuit
- Mounjaro: Also known as tirzepatide, is a groundbreaking medication for type 2 diabetes developed by Eli Lilly and Company. It works by activating two specific receptors in the body to regulate blood sugar levels. This class of drugs, which includes Ozempic and Wegovy, is known as GLP-1 receptor agonists.
- Mounjaro Eye Problems: However, recent reports have raised concerns about potential vision problems associated with Mounjaro use. Some patients have experienced temporary or even permanent loss of sight after starting this medication. As a result, healthcare professionals, regulatory bodies, and lawyers are paying closer attention to these issues.
- Mounjaro Vision Loss Lawsuit: In response to these developments, affected individuals are taking legal action against Eli Lilly and Company. They claim that the company failed to adequately warn them about the risks of eye complications associated with Mounjaro.]
- Consumer Guide: This guide aims to provide valuable information on the relationship between Mounjaro and vision issues in 2025. It covers various aspects such as how the drug works, known side effects, ongoing lawsuits, eligibility criteria for filing claims, and precautions for current users of tirzepatide-based treatments.
Understanding Mounjaro and Its Medical Use
Mechanism of Action: Mounjaro works in a unique way that sets it apart from other diabetes treatments. It contains a synthetic peptide called tirzepatide, which activates two specific receptors in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Dual Action Mechanism: By targeting these receptors simultaneously, Mounjaro enhances insulin secretion when blood sugar levels rise, reduces the release of glucagon (a hormone that raises blood sugar), and slows down the emptying of the stomach to prevent rapid spikes in blood sugar after meals. This dual action mechanism provides more comprehensive control over blood sugar levels compared to medications that only target one receptor.
How Mounjaro Compares to Other GLP-1 Drugs
- GLP-1 receptor agonists: Mounjaro belongs to a class of medications known as GLP-1 receptor agonists, which are commonly prescribed for type 2 diabetes and weight management. Other well-known drugs in this category include Ozempic (semaglutide) and Wegovy (also semaglutide but at higher doses specifically approved for chronic weight management).
- Dual Mechanism of Action: While Ozempic and Wegovy primarily act on the GLP-1 receptor alone, Mounjaro’s unique mechanism of action involving both GIP and GLP-1 receptors theoretically offers greater effectiveness in controlling blood sugar levels and promoting weight loss.
- Studies: Clinical studies have shown promising results supporting this hypothesis: tirzepatide has demonstrated superior reductions in HbA1c (a marker of long-term blood sugar control) and more significant weight loss compared to semaglutide when directly compared head-to-head. However, it’s important to note that individual patient responses may vary based on various factors such as metabolism and adherence to treatment.
Should I Report Mounjaro Side Effects?
Yes, the FDA encourages individuals who have experienced problems related to Mounjaro to report them through the MedWatch Voluntary Reporting Form or by calling 1-800-332-1088.
Be sure to provide comprehensive details about any Mounjaro vision side effects or other eye problems you have experienced.
The FDA also advises safely disposing of unused Zepbound at authorized drug take-back locations. If no centers are nearby, follow official FDA instructions for safe disposal.
Who Can Benefit from Mounjaro?
Who Benefits: Healthcare professionals typically prescribe Mounjaro for adults with type 2 diabetes who need better control over their blood sugar levels beyond what can be achieved through diet, exercise, and metformin alone. Specifically, it may be recommended for patients who:
- Have HbA1c levels above target ranges despite being on first-line therapies
- Are dealing with obesity or overweight conditions that make managing diabetes more challenging
- Cannot use insulin therapy or sulfonylureas due to concerns about low blood sugar episodes
- Want medications with proven cardiovascular benefits backed by clinical evidence
- Prefer once-weekly injections as a way to improve adherence to their medication regimen
What Are the Goals of Using Mounjaro?
- Primary Objective: The main objective behind using Mounjaro is to achieve long-lasting control over blood sugar levels. This is crucial because uncontrolled diabetes can lead to serious complications affecting various organs such as kidneys, nerves, and cardiovascular systems over time.
- Complications: By effectively managing blood sugar levels through this medication, healthcare providers aim to reduce the risk of developing these long-term complications associated with diabetes
Vision Side Effects Linked to Mounjaro
Common Ocular Side Effects
- Mounjaro Eye Problems: Patients prescribed Mounjaro have reported a range of Mounjaro vision side effects varying from mild discomfort to severe visual disturbances.
- Mounjaro Vision Side Effects: Clinical observations and patient testimonials show that Mounjaro and vision loss occur through different mechanisms, with some directly caused by the medication’s pharmacological action and others resulting from metabolic changes induced by tirzepatide therapy.
- Blurry vision: Is one of the most commonly reported Mounjaro vision problems among Mounjaro users. This condition usually happens when blood sugar levels fluctuate rapidly during the early stages of treatment. The lens of the eye swells or shrinks in response to these glycemic fluctuations, temporarily changing its focusing ability and affecting clear vision. Patients describe this issue as difficulty seeing objects clearly, especially while reading or driving.
- Eye floaters: Are another frequent Mounjaro vision problems, appearing as small dark spots, cobweb-like strands, or shadowy shapes that move across the visual field. These floaters are caused by changes in the vitreous humor—the gel-like substance filling the eye cavity. While they are usually harmless, a sudden increase in floaters accompanied by flashes of light requires immediate eye examination to rule out retinal problems.
Secondary Complications and Less Common Effects
- Mounjaro Dry eye syndrome: Is a significant secondary complication affecting Mounjaro users. The medication’s impact on metabolic processes may reduce tear production or change tear composition, leading to:
- Persistent grittiness or burning sensations in the eyes
-
- Increased sensitivity to light and environmental irritants
-
- Excessive tearing as a compensatory mechanism
-
- Redness and inflammation of the ocular surface
- Other Mounjaro eye problems: Include conjunctivitis, eyelid inflammation, and temporary changes in color perception. Some patients experience photophobia (light sensitivity) or difficulty adjusting to low-light conditions. These effects, although less common than blurry vision or floaters, need to be documented and monitored to identify patterns of occurrence and severity across different patient groups.
NAION and Mounjaro: A Closer Look at the Linkage
- Nonarteritic Anterior Ischemic Optic Neuropathy (NAION): Represents one of the most serious ocular complications associated with Mounjaro use, distinguishing itself from the more common vision disturbances through its potential for permanent vision impairment. This condition occurs when blood flow to the optic nerve becomes compromised, resulting in sudden, painless vision loss that typically affects one eye. The clinical significance of NAION extends beyond temporary visual disruption; patients may experience irreversible damage to their visual field, color perception deficits, and in severe cases, complete blindness in the affected eye.
- Mounjaro and Vision Loss: The pathophysiology of NAION involves optic nerve ischemia, a process wherein inadequate blood supply reaches the anterior portion of the optic nerve head. This vascular insufficiency causes nerve tissue death, creating a characteristic pattern of vision loss that often manifests as an altitudinal defect—a horizontal division in the visual field where the upper or lower half becomes darkened or absent. The condition develops rapidly, with most patients noticing maximum vision loss within hours to days of onset, leaving minimal opportunity for intervention once symptoms appear.
Scientific Evidence and Risk Elevation
- Mounjaro Vision Side Effects: Research examining the relationship between GLP-1 receptor agonists and NAION has revealed concerning patterns of increased incidence among users of medications like tirzepatide. Studies published in peer-reviewed medical journals have documented statistically significant elevations in NAION risk among patients prescribed these medications compared to those using alternative diabetes treatments. The risk appears particularly pronounced in individuals with pre-existing vascular risk factors, including hypertension, sleep apnea, and cardiovascular disease.
- The proposed mechanisms linking tirzepatide to optic nerve ischemia involve multiple physiological pathways:
- Alterations in blood pressure regulation affecting perfusion pressure to the optic nerve head
- Changes in vascular tone that may compromise microcirculation in vulnerable optic nerve tissue
- Metabolic shifts influencing endothelial function and blood vessel integrity
- Inflammatory responses potentially triggering vascular dysfunction in susceptible individuals
Other Vision Problems Associated with Mounjaro Use
- Mounjaro Eye Problems: The range of vision problems caused by Mounjaro goes beyond NAION and includes various eye complications that affect patients through different underlying mechanisms. To understand these additional vision-related side effects, we need to look at both direct interactions with the drug and indirect metabolic effects.
Diabetic Retinopathy Complications
- Diabetic retinopathy: Is a condition where the small blood vessels in the retina become damaged over time. This is a common problem for people with diabetes. When starting Mounjaro treatment, there are specific concerns for patients who already have diabetic retinopathy.
Potential Risks for Diabetic Retinopathy Patients Starting Mounjaro
- Increased leakage of fluid from retinal capillaries
- Faster growth of abnormal blood vessels (neovascularization)
- Worsening of swelling in the macula (macular edema)
- Gradual decline in eyesight
- Medical guidelines: Suggest that patients with known diabetic eye disease should have thorough eye exams before starting Mounjaro treatment. Additionally, closer monitoring should be done during the early stages of therapy.
Hypoglycemia-Induced Vision Disturbances
- Hypoglycemia: Refers to low blood sugar levels, which can lead to various vision problems in individuals using Mounjaro, especially when combined with insulin or sulfonylurea medications.
How Hypoglycemia Affects Vision
- When blood sugar levels drop too low, it can trigger immediate visual symptoms through different mechanisms affecting the eyes and brain:
- Temporary swelling of the lens, resulting in changes in vision
- Disruption of glucose metabolism in the retina, impacting the function of light-sensitive cells (photoreceptors)
- Insufficient glucose supply to the visual cortex, impairing processing of visual information
- Activation of the autonomic nervous system, influencing pupil responses
- These vision disturbances caused by hypoglycemia usually present as blurry vision, double vision, difficulty focusing, or temporary loss of parts of the visual field. While these symptoms typically improve once blood sugar levels return to normal, repeated episodes of hypoglycemia may have long-term effects on eyesight.
Legal Concerns Surrounding Mounjaro Vision Loss Lawsuits In 2025
- Mounjaro vision loss lawsuits: have emerged against Eli Lilly and Company, the pharmaceutical manufacturer of tirzepatide. These legal actions center on allegations that the company failed to provide adequate warnings regarding the serious ocular risks associated with the medication. Plaintiffs assert that Eli Lilly possessed knowledge of potential vision-threatening complications yet did not sufficiently communicate these dangers to healthcare providers and patients through product labeling, prescribing information, or direct consumer warnings.
- The litigation landscape: Includes claims from individuals who developed NAION, diabetic retinopathy complications, and other significant vision impairments after using Mounjaro for type 2 diabetes management. Legal filings document cases where patients experienced sudden, irreversible vision loss without prior indication of such severe risks in the medication’s official documentation. These lawsuits argue that proper disclosure would have enabled patients and physicians to make more informed treatment decisions, potentially selecting alternative therapies with different risk profiles.
- Failure to Warn: Eli Lilly faces accusations of negligence, failure to warn, and design defect in the formulation and marketing of Mounjaro. The legal theory underlying these claims posits that pharmaceutical manufacturers bear responsibility for conducting thorough safety research, monitoring post-market adverse events, and updating product warnings as new safety data emerges. Plaintiffs contend that the company did not fulfill these obligations despite accumulating evidence from clinical observations and scientific studies indicating elevated NAION risk among GLP-1 receptor agonist users.
- Litigation Expanding: The scope of pending litigation continues to expand as additional patients come forward with documented vision injuries. Law firms specializing in pharmaceutical product liability have begun consolidating cases to streamline discovery processes and establish consistent legal arguments. The judicial proceedings will likely examine internal company communications, clinical trial data, post-marketing surveillance records, and expert testimony from ophthalmologists and endocrinologists regarding the foreseeability of vision-related complications associated with tirzepatide therapy.
Eligibility And Process for Filing a Mounjaro Vision Loss Lawsuit
Eligibility: Patients who have experienced vision complications while using Mounjaro may qualify to pursue legal action against Eli Lilly under specific conditions. The Mounjaro Vision Loss Lawsuit eligibility criteria require individuals to demonstrate a documented history of tirzepatide use prescribed for type 2 diabetes or weight management.
Mounjaro Vision Side Effects: Claimants must establish that they developed Mounjaro eye problems during or shortly after treatment with the medication, particularly conditions such as NAION, severe diabetic retinopathy progression, or other significant ocular complications that resulted in measurable vision impairment.
If You Suffered from Mounjaro Vision Side Effects, Contact Mounjaro Vision Loss Lawyer Timothy L. Miles Today
If you were prescribed Mounjaro and took it as directed and suffered Mounjaro eye problems, contact Mounjaro Vision Loss Lawyer Timothy L. Miles today. You could be eligible for a Mounjaro vision loss lawsuit and potentially entitled to substantial compensation.
The call is free and so is the fee unless we win or settle your case, so give a Mounjaro vision loss Lawyer a call today. (855) 846–6529 or [email protected]
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Frequently Asked Questions
What are the symptoms of Mounjaro and Gastroparesis?
Symptoms of gastroparesis (stomach paralysis) include chronic vomiting, severe abdominal pain, nausea, and a feeling of fullness after eating very little. Many patients report these symptoms persisting even after stopping the medication.
Can I join the Mounjaro Stomach Paralysis Lawsuit if I have been diagnosed with gastroparesis?
Yes. If you used Mounjaro and were subsequently diagnosed with gastroparesis or severe intestinal blockage, you may be eligible for the federal MDL 3094 litigation.
Is a gastric emptying study required for a Mounjaro Stomach Paralysis Lawsuit?
Following recent 2026 evidentiary rulings, a formal gastric emptying study is often the strongest proof of injury required by the court to qualify for a settlement.
What is the average settlement for a Mounjaro Stomach Paralysis Lawsuit?
While global settlements are still being determined in 2026, legal experts estimate that severe cases involving permanent injury or surgery could reach between $400,000 and $700,000.
How long do I have to file a claim for Mounjaro Stomach Paralysis Lawsuit?
Statute of limitations varies by state, but with the 2026 MDL progression, it is critical to file your claim as soon as possible after a diagnosis to ensure your rights are protected.
SUBMIT YOUR INFORMATION